Clinical Evidence: Comparing Wegovy and Mounjaro Mechanisms
Understanding Prescription Weight Loss: Wegovy vs Mounjaro Mechanisms
When evaluating whether Wegovy is better than Mounjaro for prescription weight loss, the fundamental difference lies in their mechanisms of action. Wegovy contains semaglutide, a GLP-1 receptor agonist that mimics your body's natural incretin hormone to promote satiety and reduce appetite. Mounjaro utilises tirzepatide, a dual agonist targeting both GIP and GLP-1 receptors, offering a broader hormonal approach to weight management.
Both medications represent significant advances in prescription weight loss treatment, requiring clinical assessment to determine suitability. The question of whether Wegovy is better than Mounjaro ultimately depends on individual patient factors, medical history, and response to treatment. EverydayMeds provides access to both options through our comprehensive clinical assessment process, ensuring patients receive evidence-based recommendations tailored to their specific circumstances and weight management goals.
Wegovy vs Mounjaro Pricing: UK Treatment Costs Compared
Understanding the cost implications when deciding if Wegovy is better than Mounjaro requires examining both medications' pricing structures. Wegovy follows a graduated dosing schedule starting at £79.99 for the 0.25mg starter dose, progressing through £94.99 (0.5mg), £99.99 (1mg), £139.99 (1.7mg), to £209.99 for the 2.4mg maintenance dose. Our Intro Duo bundle (0.25mg & 0.5mg) provides convenient starting treatment for £169.99, whilst the Ultimate Stability Trio offers three months of maintenance supply at 2.4mg for £649.99.
Both treatments are available through EverydayMeds with discount codes applied at checkout — new customers use FIRST40 whilst returning customers benefit from DOSE25. The pricing reflects the complex manufacturing requirements for these prescription-only medicines, alongside the comprehensive clinical support provided throughout your weight management journey. When considering whether Wegovy is better than Mounjaro, cost represents just one factor amongst efficacy, tolerability, and practical considerations that our clinical team helps you evaluate.
Clinical Trial Evidence: Wegovy's Weight Loss Performance
The STEP clinical trial programme provides robust evidence for Wegovy's efficacy in prescription weight loss treatment. In the landmark STEP 1 trial published by Wilding et al. in NEJM 2021, patients taking Wegovy alongside diet and exercise achieved approximately 15% average weight loss at 68 weeks, compared to 2.4% with placebo. The STEP 5 trial demonstrated sustained clinically studied weight loss maintained over two years of continued treatment.
When evaluating whether Wegovy is better than Mounjaro, it's important to note that direct head-to-head comparison trials haven't been conducted, making definitive superiority claims inappropriate. The SELECT cardiovascular outcomes trial showed Wegovy reduced major cardiovascular events by 20% (HR 0.80), adding significant clinical value beyond weight management. Both medications require ongoing treatment alongside a reduced-calorie diet and increased physical activity to maintain their beneficial effects.
How Wegovy Works: GLP-1 Mechanism for Weight Management
Wegovy functions as a GLP-1 receptor agonist, mimicking the action of glucagon-like peptide-1, a natural hormone that regulates appetite and food intake. This mechanism works primarily in the brain's appetite centres, reducing hunger signals and promoting feelings of fullness after smaller meals. The medication may also slow gastric emptying, extending satiety between meals and potentially reducing food cravings throughout the day. Clinical studies suggest this hormonal approach addresses both the psychological and physiological aspects of weight management, supporting long-term behavioural changes. Understanding this mechanism helps patients recognise why Wegovy requires consistent use alongside lifestyle modifications to achieve optimal results in prescription weight loss treatment.
Ordering Wegovy: Your 3-Minute Assessment Process
Starting your prescription weight loss journey with Wegovy begins with our streamlined 3-minute online clinical assessment, designed to evaluate your suitability for treatment safely and efficiently. The assessment covers your medical history, current medications, weight management goals, and any contraindications that might affect treatment selection. Following submission, our qualified prescribers review your information within standard 3 working days, with express 24-hour review available for urgent requirements. Once approved, Wegovy ships via next-day delivery using temperature-controlled cold-chain logistics to maintain medication integrity. This comprehensive process ensures you receive appropriate clinical oversight whilst accessing convenient, professional weight management support through our GPhC-registered pharmacy service.
Storage and Practical Considerations: Wegovy's Travel Advantage
Wegovy's storage requirements offer practical advantages when considering whether this treatment is better than Mounjaro for your lifestyle needs. The FlexTouch pen system requires refrigeration at 2-8°C before first use but maintains stability for up to 6 weeks at room temperature below 30°C once removed from refrigeration. This extended room-temperature stability exceeds Mounjaro's 21-day limit, providing greater flexibility for travel, work schedules, or temporary storage situations. The once-weekly injection schedule follows a mandatory dose escalation protocol starting at 0.25mg and gradually increasing to the 2.4mg maintenance dose over 16 weeks. This graduated approach minimises potential side effects whilst allowing your body to adjust to the medication's appetite-suppressing effects throughout your weight management programme.
Professional Prescriber Guidance: Choosing Between Weight Loss Treatments
The decision of whether Wegovy is better than Mounjaro requires individualised clinical assessment rather than generalised recommendations. Factors influencing treatment selection include your medical history, concurrent medications, previous weight loss attempts, and specific health comorbidities that might favour one mechanism over another. Our clinical team at EverydayMeds evaluates these variables alongside your personal preferences regarding dosing frequency, storage requirements, and treatment goals.
Both medications represent evidence-based approaches to prescription weight loss, each with distinct advantages depending on patient circumstances. Professional prescriber input ensures you receive treatment aligned with NICE guidance TA875, which recommends specialist weight management support alongside medication therapy. Rather than determining which treatment is universally better, our focus centres on identifying the most appropriate option for your individual weight management journey through comprehensive clinical evaluation.
Comprehensive Weight Management: Beyond Medication Selection
Successfully determining whether Wegovy is better than Mounjaro extends beyond comparing medications to encompassing your complete weight management strategy. Both treatments require commitment to lifestyle modifications, including reduced-calorie diet and increased physical activity, to achieve optimal results. EverydayMeds provides ongoing clinical support throughout your treatment journey, monitoring progress and adjusting recommendations as needed. Our approach recognises that prescription weight loss represents one component of comprehensive health management rather than a standalone solution.
Weight regain remains a consideration with both treatments, as clinical evidence shows patients may regain approximately two-thirds of lost weight within one year of stopping medication. This emphasises the importance of viewing prescription weight loss treatment as a long-term commitment supported by sustained lifestyle changes. Both Wegovy and Mounjaro are available through EverydayMeds, ensuring you have access to expert clinical guidance regardless of which treatment proves most suitable for your circumstances.
Reviewed by the EverydayMeds Clinical Team · GPhC #9012878 · Last updated February 2026
